Tyra Biosciences, Inc.
Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines for targeted oncology and genetically defined conditions by harnessing Fibroblast Growth Factor Receptor (FGFR) biology. The company trades on the NASDAQ under ticker symbol TYRA and maintains its… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tyra Biosciences, Inc. does
In the company’s own words
Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines for targeted oncology and genetically defined conditions by harnessing Fibroblast Growth Factor Receptor (FGFR) biology. The company trades on the NASDAQ under ticker symbol TYRA and maintains its website at www.tyra.bio.
The company's core business centers on its proprietary SNÅP platform, which enables rapid and precise drug design through iterative molecular snapshots that help predict which product candidates will demonstrate the highest potency, selectivity, and tolerability in clinical settings. This platform integrates three key pillars: protein crystallography techniques that determine co-crystal structures within three days, cell-based assays that assess inhibitor potency in two days, and in vivo models that provide pharmacologic data within five days. Together, these capabilities enable the company to generate comprehensive molecular snapshots for compound candidates within one week.
Tyra's pipeline is wholly owned and developed in-house, with the lead program being oral dabogratinib, designed to be highly selective for FGFR3 over other FGFR isoforms to minimize off-target side effects. The company is advancing dabogratinib through three Phase 2 trials targeting three major indications: low-grade upper tract urothelial carcinoma (SURF303), intermediate-risk non-muscle invasive bladder cancer (SURF302), and achondroplasia in children (BEACH301). This "dabogratinib 3x3" strategy represents the company's approach to addressing large market opportunities across both oncology and rare genetic conditions.
Beyond its lead program, Tyra is developing TYRA-430, an FGFR4/3 biased inhibitor for FGF19-positive hepatocellular carcinoma, and TYRA-200, an FGFR1/2/3 inhibitor designed to address acquired resistance mutations in intrahepatic cholangiocarcinoma. The company has built a substantial intellectual property portfolio consisting of three granted U.S. patents, pending U.S. and international applications, with expected patent expirations ranging from 2040 to 2046 before accounting for potential patent term extensions.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 1863127
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tyra Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tyra Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tyra Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tyra Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tyra Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”